Clinical TrialJun 11, 2026, 07:11 AM
Nurix Therapeutics: Bexobrutideg Shows 92.9% ORR in CLL/SLL
AI Summary
Nurix Therapeutics announced updated Phase 1a/1b clinical data for its novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), to be presented at EHA2026. The data demonstrated a favorable safety profile and durable responses, with an objective response rate (ORR) of 83.0% and a median progression-free survival (PFS) of 22.1 months in heavily pretreated patients. In earlier-line cohorts, ORR reached 92.9% in BTKi-treated, BCL2i-naïve patients and 84.2% in BTKi-naïve patients.
Key Highlights
- Bexobrutideg was well tolerated across 142 CLL/SLL patients; no dose-limiting toxicities or treatment-related Grade 5 adverse events.
- Phase 1a (relapsed/refractory) showed an objective response rate (ORR) of 83.0% among 47 evaluable patients, including 2 complete responses.
- Median progression-free survival (PFS) in Phase 1a was 22.1 months (95% CI: 14.0–NR) with a median follow-up of 22.4 months.
- Responses were observed across difficult-to-treat subgroups, including patients with BTK inhibitor resistance mutations, high-risk molecular features, and CNS involvement.
- Phase 1b Cohort 5 (BTKi-treated, BCL2i-naïve) achieved an ORR of 92.9% among 14 evaluable patients.
- Phase 1b Cohort 15 (BTKi-naïve) achieved an ORR of 84.2% among 19 evaluable patients.
- Treatment discontinuations due to adverse events occurred in only 5.6% of patients across the Phase 1a/1b population.
Price Impact
More from NRIX